Treatment of vancomycin-resistant Enterococcus faecium with RP 59500 (quinupristin-dalfopristin) administered by intermittent or continuous infusion, alone or in combination with doxycycline, in an in vitro pharmacodynamic infection model with simulated endocardial vegetations.

@article{Aeschlimann1998TreatmentOV,
  title={Treatment of vancomycin-resistant Enterococcus faecium with RP 59500 (quinupristin-dalfopristin) administered by intermittent or continuous infusion, alone or in combination with doxycycline, in an in vitro pharmacodynamic infection model with simulated endocardial vegetations.},
  author={Jeffrey R. Aeschlimann and Marcus John Zervos and Michael Joseph Rybak},
  journal={Antimicrobial agents and chemotherapy},
  year={1998},
  volume={42 10},
  pages={2710-7}
}
Quinupristin-dalfopristin is a streptogramin antibiotic combination with activity against vancomycin-resistant Enterococcus faecium (VREF), but emergence of resistance has been recently reported. We studied the activity of quinupristin-dalfopristin against two clinical strains of VREF (12311 and 12366) in an in vitro pharmacodynamic model with simulated endocardial vegetations (SEVs) to determine the potential for resistance selection and possible strategies for prevention. Baseline MICs… CONTINUE READING

From This Paper

Figures, tables, and topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 13 extracted citations

Quinupristin-dalfopristin resistance in gram-positive bacteria: mechanism of resistance and epidemiology.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America • 2004
View 5 Excerpts

References

Publications referenced by this paper.
Showing 1-10 of 38 references

The pharmacokinetics of quinupristin/dalfopristin in laboratory animals and in humans.

The Journal of antimicrobial chemotherapy • 1997
View 3 Excerpts
Highly Influenced

In vitro evaluation of the development of Synercidt resistant mutants in Enterococcus faecium, abstr

L. A. Thal, A. Davison, J. Chow, M. Zervos
1996
View 5 Excerpts
Highly Influenced

Efficacy and safety of quinupristin/ dalfopristin (Synercid) in the treatment of vancomycin-resistant Enterococcus faecium (VREF) infections, abstr

R. L. Moellering, P. K. Linden
1998
View 1 Excerpt

Emergence of increased resistance to quinupristin/dalfopristin during therapy for Enterococcus faecium bacteremia.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America • 1997
View 3 Excerpts

In-vitro and in-vivo antibacterial activity of quinupristin/dalfopristin.

The Journal of antimicrobial chemotherapy • 1997
View 1 Excerpt

Low rates of emerging resistance and superinfection in Synercid (quinupristin/ dalfopristin, Q/D) treated patients during worldwide clinical program

H. Nadler, M. Dowzicky, G. Talbot, F. Bompart, F. Grote
abstr. E-136B, • 1997
View 1 Excerpt

Similar Papers

Loading similar papers…